Allarity Therapeutics (NASDAQ:ALLR – Get Free Report) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share guidance of -0.760–0.730 for the period, compared to the consensus earnings per share estimate of -0.800. Allarity Therapeutics also updated its Q4 2026 guidance to 0.010-0.040 EPS.
Allarity Therapeutics Stock Performance
Shares of ALLR opened at $0.91 on Friday. Allarity Therapeutics has a 1 year low of $0.77 and a 1 year high of $1.84. The stock’s 50-day moving average price is $1.02 and its two-hundred day moving average price is $1.21.
Allarity Therapeutics (NASDAQ:ALLR – Get Free Report) last posted its earnings results on Friday, November 13th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.18). The firm had revenue of $0.01 million during the quarter. Allarity Therapeutics has set its FY 2026 guidance at -0.760–0.730 EPS and its Q4 2026 guidance at 0.010-0.040 EPS. On average, research analysts forecast that Allarity Therapeutics will post -0.80 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Thursday, October 15th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $10.25.
Check Out Our Latest Report on ALLR
About Allarity Therapeutics
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biotechnology company focused on developing personalized treatments for cancer. The company uses its Drug Response Predictor (DRP) technology to analyze patient and tumor characteristics and identify individuals who may be more likely to respond to specific drug candidates. Allarity’s development programs have included stenoparib, also known as 2X-121, an orally administered PARP inhibitor being investigated for potential use in oncology.
Read More
- Five stocks we like better than Allarity Therapeutics
- These 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?
- Golden Dome’s $185 Billion Question: Who Actually Gets Paid?
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
Receive News & Ratings for Allarity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allarity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
